CONCISE CLINICAL REVIEW

Role of Biologics in Asthma

Mary Clare McGregor1, James G. Krings1, Parameswaran Nair2, and Mario Castro1
1
Division of Pulmonary and Critical Care, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri;
and 2Division of Respirology, Department of Medicine, St. Joseph’s Healthcare Hamilton, McMaster University, Hamilton, Ontario,
Canada

Abstract recently emerged as promising treatments for T2 asthma. These

targeted therapies have been shown to reduce asthma exacerbations,
Patients with severe uncontrolled asthma have disproportionally improve lung function, reduce oral corticosteroid use, and improve
high morbidity and healthcare utilization as compared with their quality of life in appropriately selected patients. In addition to the
peers with well-controlled disease. Although treatment options for currently approved biologic agents, several biologics targeting
these patients were previously limited, with unacceptable side effects, upstream inflammatory mediators are in clinical trials, with possible
the emergence of biologic therapies for the treatment of asthma has approval on the horizon. This article reviews the mechanism of
provided promising targeted therapy for these patients. Biologic action, indications, expected benefits, and side effects of each of the
therapies target specific inflammatory pathways involved in the currently approved biologics for severe uncontrolled asthma and
pathogenesis of asthma, particularly in patients with an endotype discusses promising therapeutic targets for the future.
driven by type 2 (T2) inflammation. In addition to anti-IgE therapy
that has improved outcomes in allergic asthma for more than a Keywords: severe asthma; eosinophils; asthma treatments;
decade, three anti–IL-5 biologics and one anti–IL-4R biologic have biologics; monoclonal antibodies

Asthma is a chronic inflammatory disorder uncontrolled asthma carry much of the variety of pathophysiologic mechanisms, or
of the airways characterized by bronchial morbidity, mortality, and healthcare endotypes (7–10). There are two specific
hyperresponsiveness and variable airflow utilization of the disease (2, 4). Specifically, endotypes, type 2 (T2) high and low,
limitation that affects more than 300 million patients with severe asthma have increased that are important to distinguish when
people worldwide (1). Although the hospitalizations, detrimental side effects of considering biologic therapy. These
majority of patients with asthma can oral corticosteroids (OCS), poor quality endotypes are defined based on their level
achieve disease control with standard of life (QOL), and impaired lifestyle as of expression of cytokines such as IL-4,
controller therapy, approximately 5% have compared with patients with well-controlled IL-5, and IL-13 that may be secreted by the
severe asthma that remains inadequately disease (5). classic T-helper cell type 2 (Th2)-type cells,
controlled despite adherence to standard Over the past decade, an improved such as the CD4 lymphocytes, or nonclassic
treatment with a high-dose inhaled understanding of the complex pathophysiology immune cells, such as the innate lymphoid
corticosteroid (ICS) plus long-acting of asthma has led to the development cells–type 2 (ILC-2) (hence, the change
bronchodilator (2). Severe asthma is of new treatment options for asthma. in terminology from Th2 to T2). Biologic
defined by the European Respiratory Today, patients with uncontrolled severe therapies target inflammatory modulators
Society/American Thoracic Society as asthma are routinely considered for that have been identified to play a key role
asthma that requires treatment with candidacy of biologic therapies as well as for in the pathogenesis of asthma predominantly
high-dose ICS plus a second controller bronchial thermoplasty (6). Researchers in the T2-high subset of patients and
with or without systemic corticosteroids and clinicians have increasingly recognized have demonstrated encouraging
to maintain control of the disease or, that asthma is not a uniform disease results specifically in this group. This
despite this therapy, have suboptimally but rather a heterogeneous disease with article reviews the mechanism of action,
controlled disease (3). Patients with severe multiple phenotypes that are caused by a efficacy, and indications of the currently

( Received in original form October 16, 2018; accepted in final form December 6, 2018 )
Correspondence and requests for reprints should be addressed to Mario Castro, M.D., M.P.H., Division of Pulmonary and Critical Care Medicine, Department
of Medicine, Washington University School of Medicine, 660 S. Euclid Avenue, Campus Box 8052, St. Louis, MO 63110. E-mail: castrom@wustl.edu.
CME will be available for this article at www.atsjournals.org.
Am J Respir Crit Care Med Vol 199, Iss 4, pp 433–445, Feb 15, 2019
Copyright © 2019 by the American Thoracic Society
Originally Published in Press as DOI: 10.1164/rccm.201810-1944CI on December 10, 2018
Internet address: www.atsjournals.org

Concise Clinical Review 433

 CONCISE CLINICAL REVIEW

approved biologics (Table 1), discusses which subsequently leads to activation inflammation that can help predict response
considerations when choosing between of mediators such as thymic stromal to biologics (14).
these biologics (Table 2), and reviews lymphopoietin (TSLP), IL-25, and
potential therapeutic targets for the future IL-33 (Figure 1). This process leads to T2-Low Asthma
(Table 3). activation of IL-4, IL-5, and IL-13, T2-low asthma, which includes
which can result in attraction and neutrophilic, mixed, or paucigranulocytic
activation of basophils, eosinophils, and asthma, has a comparatively poorly
Type 2 High and Low Airway mast cells; secretion of IgE by B cells; and understood pathophysiology and may be
Inflammation activation of innate cells such as the influenced by the concomitant use of
airway epithelium and smooth muscle, corticosteroids suppressing underlying
The treatment of asthma is moving toward a resulting in bronchoconstriction, airway eosinophilia. T2-low asthma is caused
personalized treatment strategy that is based hyperresponsiveness, mucus production, by neutrophilic or paucigranulocytic
on patient-specific characteristics and and airway remodeling (12, 13). T2-high inflammation that results in activation of
underlying endotype rather than disease asthma encompasses both allergic and both T1 and T17 cells, and high IL-17A
severity alone. nonallergic eosinophilic asthma. Although mRNA levels have been found in patients
an allergen-specific, IgE-dependent process with moderate to severe asthma (15). These
T2-High Asthma plays a significant role in allergic asthma, patients are generally less responsive to
T2 inflammation occurs in approximately T2 cytokines play a dominant role in corticosteroids, have fewer allergic symptoms,
half of patients with asthma and may inflammation in nonallergic eosinophilic and are older at the time of diagnosis.
be slightly more common in patients asthma. Sputum and blood absolute Currently, there is no approved biologic
with severe asthma (11). In T2-high eosinophil counts (AECs), serum IgE, for T2-low asthma, and thus therapy in
asthma, inhaled allergens, microbes, and exhaled nitric oxide, and serum periostin this group relies on standard treatment
pollutants interact with the airway epithelium, are all important biomarkers of T2 with controller medications and possible

Table 1. Summary of the Biologics Currently Approved for the Treatment of Moderate to Severe Persistent Asthma with
Type 2–High Phenotype

Therapy Mechanism of Action Indication Dosing and Route Adverse Effects

Omalizumab Anti-IgE; prevents IgE >6 yr old with moderate to severe 0.016 mg/kg per IU of IgE Black box warning:
from binding to its persistent asthma, positive allergy (in a 4-wk period) z0.1–0.2% risk of
receptor on mast testing, incomplete control with an administered every 2–4 anaphylaxis in clinical
cells and basophils ICS, and IgE: 30–1,300 IU/ml wk s.c. (150–375 mg in trials
(United States, age 6–11 yr), 30–700 United States; 150–600
IU/ml (United States, age > 12 yr), mg in European Union)*
or 30–1,500 IU/ml (European Union)

Mepolizumab Anti–IL-5; binds to IL-5 >12 yr old with severe eosinophilic 100 mg s.c. every 4 wk Rarely causes
ligand; prevents IL-5 asthma unresponsive to other GINA hypersensitivity
from binding to its step 4–5 therapies. Suggested reactions; can cause
receptor AEC > 150–300 cells/ml activation of zoster

Reslizumab Anti–IL-5; binds to IL-5 >18 yr old with severe eosinophilic Weight-based dosing of Black box warning:
ligand; prevents IL-5 asthma unresponsive to other GINA 3 mg/kg i.v. every 4 wk z0.3% risk of
from binding to its step 4–5 therapies. Suggested anaphylaxis in clinical
receptor AEC > 400 cells/ml trials

Benralizumab Anti–IL-5; binds to IL-5 >12 yr old with severe eosinophilic 30 mg s.c. every 4 wk for Rarely causes
receptor a; causes asthma unresponsive to other GINA three doses; followed hypersensitivity
apoptosis of step 4–5 therapies. Suggested by every 8 wk reactions
eosinophils and AEC > 300 cells/ml subsequently
basophils

Dupilumab Anti–IL-4R; binds to IL-4 >12 yr old with severe eosinophilic 200 or 300 mg s.c. Rarely causes
receptor a; blocks asthma unresponsive to other GINA every 2 wk hypersensitivity
signaling of IL-4 and step 4–5 therapies. Suggested reactions; higher
IL-13 AEC > 150 cells/ml and/or FENO incidence of injection site
level > 25 ppb reactions (up to 18%)
and hypereosinophilia
(4–14%)

Definition of abbreviations: AEC = absolute blood eosinophil count; FENO = fractional exhaled nitric oxide; GINA = Global Initiative for Asthma; ICS = inhaled
corticosteroids.
*Upper limits exist for the dosing of omalizumab in patients with high IgE levels and increased weight.

434 American Journal of Respiratory and Critical Care Medicine Volume 199 Number 4 | February 15 2019
CONCISE CLINICAL REVIEW

Table 2. Efficacy of the Biologics That Are U.S. Food and Drug Administration Approved for the Treatment of Moderate to Severe
Persistent Asthma with Type 2–High Phenotype

Asthma
Therapy Exacerbation Lung Function Corticosteroid Weaning Special Considerations

Omalizumab Reduces by Minimal or Decreases use of ICS, but no data that Only s.c. biologic approved for children
25% equivocal it helps with OCS weaning 6–11 yr old
improvement

Mepolizumab Reduces by Inconsistent Decreases total use of OCS and has Standard s.c. dosing has not been shown
z50% effect been shown to facilitate complete to decrease sputum eosinophilia;
weaning from chronic OCS (14%) approved at higher dosing for EGPA

Reslizumab Reduces by Improved Has not been specifically evaluated Only weight-based dosing i.v. biologic
z50–60% for this indication approved for asthma

Benralizumab Reduces by Improved Decreases total use of OCS and has Only s.c. biologic that offers every-8-wk
z25–60% been shown to facilitate complete dosing
weaning from chronic OCS (50%)

Dupilumab Reduces by Improved Decreases total use of OCS and has Only biologic that can be self-administered
z50–70% been shown to facilitate complete s.c.; showed benefit with FENO > 25 ppb
weaning from chronic OCS (50%) regardless of eosinophil count

Definition of abbreviations: EGPA = eosinophilic granulomatosis with polyangiitis; FENO = fractional exhaled nitric oxide; ICS = inhaled corticosteroid;
OCS = oral corticosteroid.

bronchial thermoplasty (14). However, one can reduce exacerbations during which patients would have the greatest
recent trial suggests macrolide therapy with peak viral seasons, associated with benefit from omalizumab are ongoing.
azithromycin may have a role in reducing enhanced IFN-a production in response Retrospective analyses suggest a greater
exacerbations in patients with T2-low to rhinovirus, raising the possibility reduction in asthma exacerbations in
asthma (16). of alternate antiviral mechanisms of patients who receive omalizumab with high
action (21). eosinophil counts and high exhaled NO
Efficacy. Omalizumab has been used levels (31). However, this difference may be
Biologics clinically for the treatment of allergic asthma due to the higher rate of exacerbations in
for more than 15 years and has shown those with high T2 biomarkers, allowing
Anti-IgE: Omalizumab favorable outcomes in several randomized for a greater reduction with omalizumab.
control trials (RCTs). In 2014, a Cochrane Therefore, even patients with low T2
Mechanism of action. Omalizumab, a
review evaluating 25 RCTs in patients biomarker profiles who qualify for
humanized anti-IgE monoclonal antibody
with moderate to severe allergic asthma omalizumab may benefit from its use. A
(mAb), was the first biologic approved for
found omalizumab compared with placebo recent pragmatic trial of omalizumab
the treatment of asthma in the United
reduced asthma exacerbations by demonstrated similar benefits in patients
States and European Union. Allergic
asthma accounts for approximately 70%
approximately 25%, reduced hospitalizations, with T2-high and -low asthma (AEC ,300
of asthma, and IgE is essential in the and allowed reduction of ICS dose or >300 cells/ml and fractional exhaled
inflammatory cascade of allergic asthma (22–26) (Figure 2). Some studies have nitric oxide [FENO] ,25 or >25 ppb) (30).
(17, 18). IgE is produced by B cells in shown a small improvement in lung In addition, studies have demonstrated a
response to allergen activation of the cell- function (27), although others have not. similar benefit of omalizumab in patients
mediated immune response. Omalizumab There have been no clear data that support a who have IgE levels both higher and lower
prevents IgE from binding to its high- reduction in OCS in patients treated with than the currently approved range of
affinity receptor (FceRI) found on mast omalizumab. Many of the early trials of 30 to 700 IU/ml in the United States (30).
cells and basophils, which dampens the omalizumab were in patients with moderate Finally, in a proof-of-concept pilot study,
release of proinflammatory mediators allergic asthma; however, subsequent omalizumab decreased expression of FceRI
and blunts the downstream allergic trials in severe allergic asthma have on basophils in patients with nonatopic
response (19, 20). Omalizumab also demonstrated similar efficacy (28). Real- asthma, suggesting a possible role of
down-regulates the expression of the IgE world studies have similarly demonstrated omalizumab in a nonallergic phenotype
receptor on mast cells, further reducing a reduction in exacerbations and (32).
inflammation (20). Although these hospitalizations with omalizumab (29, 30). Indications, administration, safety. In
mechanisms are well described, clinical Efforts to better understand specific the United States, omalizumab is approved
studies have demonstrated omalizumab patient characteristics that would predict for patients aged 6 years and older who have

Concise Clinical Review 435

 CONCISE CLINICAL REVIEW

Allergens, viruses, and Tight Goblet Airway

irritants junction cell epithelium

IL-4
TSLP
Dendritic Th0
cell cell Th2 Approved drug
IL-33 IL-25 differentiation target
IL-4
Th2 CRTh2
ILC2 cell DP-1 Investigational drug
CRTh2
cell target

IL-4 IL-13
IL-13 IL-5 IL-5
Eosinophil
activation in M2 macrophage IL-13
bone marrow polarization IL-4
Eosinophil Upregulation
Bronchial
of Fibrosis enlargement
chemokines
Epithelial
Basement membrane
Inflammatory cell damage/shedding
IgE thickening
IL-4 IL-13 trafficking to the
tissue Goblet cell
CRTh2
DP-1 hyperplasia/
IL-5 Basophil Mast cell B cell class B cell mucus production
switching and
SM contractility
IgE production
IL-4 IL-13

Figure 1. Schematic of the immunopathobiology of asthma with sites of the targeted treatments with approved and investigational monoclonal antibodies
marked. In asthma, the interaction of genetic susceptibility and environmental exposures—such as with allergens, viruses, pollutants, and irritants—
creates airway inflammation. In type 2 (T2) asthma, the interaction of environmental exposures with the airway epithelium leads to the release of the
mediators IL-33, IL-25, and TSLP (thymic stromal lymphopoietin). In addition, allergens are taken up by dendritic cells and presented to naive T-helper
(Th0) cells. A cascade of events as shown ensues that leads to production of the type 2 cytokines IL-4, IL-5, and IL-13; secretion of IgE by B cells; and
chemoattraction of mast cells, eosinophils, and basophils. This process lends itself to numerous therapeutic targets that have already been approved by
the U.S. Food and Drug Administration (outlined in red) and others that remain in investigation (outlined in green). CRTh2 = chemoattractant receptor–
homologous molecule expressed on T2 cells; DP-1 = prostaglandin D2 receptor type 1; ILC2 = innate lymphoid cell type 2; M2 macrophage = alternatively
activated macrophage; SM = smooth muscle. Modified by permission from Reference 98 from Sanofi.

moderate to severe persistent asthma, with a risk of anaphylaxis of 0.1% to frequent exacerbations (9, 35–37). IL-5 is
symptoms inadequately controlled by ICS, 0.2% (34). Despite the relatively low risk the primary cytokine involved in the
positive allergy testing, and a total serum IgE of anaphylaxis, the U.S. Food and Drug recruitment, activation, and survival of
level between 30 and 1,300 IU/ml for Administration (FDA) has placed a black eosinophils, and by inhibiting this pathway,
patients 6 to 11 years old and between box warning on omalizumab, and the anti–IL-5 biologics reduce eosinophilic
30 and 700 IU/ml for patients 12 years medication should be administered in a airway inflammation (38). Mepolizumab
and older (European Union is between healthcare setting that is prepared to deal and reslizumab are both mAbs that bind
30 and 1,500 IU/ml). Omalizumab is given with anaphylaxis. Patients should be and inhibit IL-5, preventing IL-5 from
subcutaneously every 2 to 4 weeks, with observed for 2 hours after the first three binding to its receptor on eosinophils
dose and frequency based on body weight injections and then 30 minutes with and reducing downstream eosinophilic
and pretreatment IgE level. Monitoring subsequent injections. inflammation. Benralizumab is a mAb
of IgE levels during treatment is not that binds the a subunit of the IL-5
recommended. A trial of 3 to 6 months Anti–IL-5 receptor on eosinophils and basophils,
should be given to assess for clinical preventing IL-5 binding and the
response, and treatment should be Mechanism of action. A subset of subsequent recruitment and activation of
continued indefinitely if a patient has a patients with moderate to severe eosinophils. Furthermore, afucosylation
favorable response as supported by the asthma have an eosinophilic phenotype of the benralizumab mAb enhances
XPORT (Xolair Persistency of Response characterized by an increase in sputum its ability to engage with FcgRIIIa
after Long-Term Therapy) trial (33). and/or blood eosinophils despite treatment on natural killer cells, causing aggregation
Omalizumab is generally well tolerated, with corticosteroids and are more prone to around the eosinophil and resulting in

436 American Journal of Respiratory and Critical Care Medicine Volume 199 Number 4 | February 15 2019
CONCISE CLINICAL REVIEW

A Protocol-defined asthma B Effect on lung function in A recent Cochrane review found

exacerbations over 48-week INNOVATE study over 28-week that patients with eosinophilic asthma
treatment period treatment period
treated with mepolizumab had a
0.09L*
reduction in asthma exacerbations by
50% and a small increase in FEV1 of
1.0 25%** 0.20 0.19 L
110 ml over placebo. Mepolizumab

LS mean change from baseline

0.88
Exacerbation rate/patient over

0.9
48-week treatment period

resulted in a clinically and statistically

in FEV1 (L) at week 28

0.8
0.7 0.66 0.15 significant improvement in QOL as
0.6 measured by the St. George’s Respiratory
0.096 L Questionnaire. A lack of clinical
0.5 0.10
0.4 response to omalizumab does not predict
0.3 a lack of response to mepolizumab
0.05
0.2 (44).
0.1 Indications, administration, safety.
0.0 0.00 Mepolizumab is currently approved for
n=421 n=427 n=210 n=209
patients 12 years of age and older with severe
Placebo Omalizumab
asthma with an eosinophilic phenotype.
Figure 2. Effect of omalizumab on (A) rate of asthma exacerbations and (B) lung function: the EXTRA Although the FDA has not set an AEC
trial (28) and INNOVATE study (27). (A) In the EXTRA trial, when evaluated over 48 weeks, treatment
required for use, RCTs have suggested a
with omalizumab reduced the rate of asthma exacerbations by 25% (95% confidence interval,
8‒39%). (B) In the INNOVATE study, when evaluated over a 28-week period, treatment with benefit for patients with a count as low
omalizumab improved lung function, as measured by the least squares (LS) mean change in FEV1, by as 150 cells/ml, particularly in patients
94 ml more than placebo (P = 0.043). *P , 0.05; **P , 0.01. on chronic OCS (45). Mepolizumab is
administered subcutaneously every 4 weeks
at 100 mg per dose. A clinical response
antibody-directed cell-mediated cytotoxicity 40–43). In the SIRIUS trial, treatment with
should be seen within 4 months, and
and eosinophil apoptosis followed by mepolizumab led to a reduction in OCS
phagocytosis by macrophages (39). dosage by 50% in patients with eosinophilic treatment with mepolizumab should be
asthma on chronic OCS (Figure 3). This continued indefinitely if a clinical response
Mepolizumab corticosteroid-sparing effect occurred is achieved. Mepolizumab has been
while maintaining the effects of reduced demonstrated to have a safety profile
Efficacy. Mepolizumab has been studied in exacerbations (32%) and improved asthma that is similar to placebo (46). A zoster
patients with uncontrolled eosinophilic control (43). The effect of mepolizumab vaccination (preferably recombinant, not
asthma who have increased sputum on lung function has been less consistent. live virus) should be given 4 weeks before
(.3%) or AEC (>150 or >300 cells/ml). Some trials demonstrated an improvement drug initiation in those aged 50 years old
Mepolizumab has been shown to reduce in FEV1, whereas one of the largest or older. Mepolizumab is also approved for
asthma exacerbations, improve lung trials, the DREAM trial, demonstrated the treatment of eosinophilic granulomatosis
function, improve asthma control, and no significant change in FEV1 with with polyangiitis (Churg-Strauss syndrome)
reduce OCS use in multiple RCTs (35; mepolizumab (42). at a higher dose of 300 mg every 4 weeks.

A Change from Baseline in B C

Asthma Exacerbations ACQ-5 Score
Glucocorticoid Dose
40 Placebo (N=66) Maintenance Placebo
70 2.6
Mepolizumab (N=69) dose
20 2.4
Median Change (%)

60
2.2
Cumulative No.

0 50
Mean Score

2.0
–20 40
Optimized Mepolizumab
1.8
dose 30
–40 1.6
20 1.4
–60 Placebo
10 1.2
Mepolizumab
–80
0 1.0
0 4 8 12 16 20 24 0 4 8 12 16 20 24 0 4 8 12 16 20 24
Week Week Week
Figure 3. Effect of mepolizumab on (A) oral corticosteroid reduction, (B) asthma exacerbations, and (C) lung function: the SIRIUS trial. (43). (A) In
the SIRIUS trial, the reduction in steroid dosing at 24 weeks was 50% in the group receiving mepolizumab compared with 0% in the placebo group
(P = 0.007). (B) At 24 weeks, there was a relative reduction of 32% in the cumulative number of asthma exacerbations with mepolizumab (P = 0.04).
(C) Based on the Asthma Control Questionnaire 5 (ACQ-5), mepolizumab resulted in improvement in asthma control at 2 weeks that was sustained
through the 24-week trial (P = 0.004). Error bars show 95% confidence intervals around the least squares mean.

Concise Clinical Review 437

 CONCISE CLINICAL REVIEW

Reslizumab Benralizumab thereafter for maintenance. A trial of

4 months should be given to assess for
Efficacy. Reslizumab has been studied in Efficacy. Similar to the other anti–IL-5 response. Benralizumab is generally well
several RCTs in patients with uncontrolled biologics, benralizumab has been shown tolerated but has led to hypersensitivity
eosinophilic asthma and has consistently to reduce asthma exacerbation rates and reactions, including anaphylaxis, angioedema,
been shown to reduce AEC, reduce asthma improve lung function in patients with and urticaria.
exacerbations, and improve lung function uncontrolled eosinophilic asthma (52–54).
(47–49) (Figure 4). There are no studies to A 2017 Cochrane review demonstrated Selection of Anti–IL-5: Influence
date that have evaluated the OCS-sparing a significant reduction in asthma of Airway Eosinophils and Local
effect of reslizumab. One study demonstrated exacerbations in patients treated with Eosinophilopoeitic Mechanisms
no significant improvement in lung benralizumab regardless of their AEC. Although AEC correlates fairly well
function with reslizumab in patients with However, the effect of benralizumab was with airway luminal (sputum) eosinophil
AECs less than 400 cells/ml, highlighting greatest in patients with AEC greater than numbers in patients who are on low to
the importance of selecting an eosinophilic or equal to 300 cells/ml. Furthermore, moderate doses of ICS (57), there is lack
phenotype (50). A recent Cochrane review improvements in lung function and QOL of concordance in those on maintenance
found that reslizumab reduced asthma were only significant in the higher OCS (58). Persistently raised AECs
exacerbations by 50%, increased FEV1 eosinophil group (51). In the ZONDA greater than 400 cells/ml are likely to be
by 110 ml over placebo, and improved trial, benralizumab was shown to associated with sputum eosinophilia, but
QOL (51). significantly reduce OCS use by 75% in the converse is not true. Discordance
Indications, administration, safety. patients on long-term OCS with AEC between the systemic versus luminal anti-
Reslizumab is approved as add-on treatment greater than or equal to 150 cells/ml, while eosinophil effect of anti–IL-5 therapy is
for patients aged 18 years or older with reducing annualized asthma exacerbations indicative of alternative mechanisms of
severe eosinophilic asthma (AEC > 400 by 70% (55) (Figure 5). Benralizumab in situ eosinophilic inflammation, which,
cells/ml). Reslizumab is the only biologic appears to be equally effective independent when unsuppressed, may contribute
delivered intravenously using weight-based of atopy (56). to the ongoing clinical symptoms
dosing at 3 mg/kg dose every 4 weeks. The Indications, administration, safety. (59) (Figure 6). Mepolizumab 750 mg
weight-based dosing may offer a distinct Benralizumab is approved for patients 12 intravenous administered to patients
advantage over fixed doses (see selection years of age or older with uncontrolled with persistent sputum eosinophilia
of IL-5 mAb below). Reslizumab is well eosinophilic asthma (AEC > 300 (41) significantly reduced both blood
tolerated, with adverse events similar to the cells/ml) (51, 54). Benralizumab is and sputum eosinophils and allowed
placebo group. However, three cases of administered at 30 mg subcutaneously significant reduction in OCS (87% of
anaphylaxis occurred during RCTs, and every 4 weeks for the first three doses as the dose) along with improved asthma
thus reslizumab carries an FDA black box an induction phase (to reduce tissue control. In comparison, the OCS
warning (48). eosinophilia), followed by every 8 weeks reduction effect of mepolizumab at the

A Effect of reslizumab on exacerbation rate B Effect of reslizumab on FEV1

50% 59% 54%

0.13 L 0.09 L 0.11 L

2.11 0.25
*** ***
2.2 0.24 L
** 0.22 L
(events/patient-year) over 52-week

2.0
LS mean change from baseline in

1.80 1.81 0.20 L

Adjusted exacerbation rate

1.8 0.20
FEV1(L) at Week 52

1.6
treatment period

1.4
0.15
1.2 *** *** *** 0.12 L
0.11 L 0.11 L
1.0 0.90 0.86 0.84
0.10
0.8
0.6
0.4 0.05
0.2
0.0 0.00
Study 1 Study 2 Pooled Study 1 Study 2 Pooled
Study 1: Placebo q4w (N=244) Study 1: Reslizumab 3.0 mg/kg q4w (n=245) Study 2: Placebo q4w (N=232) Study 2: Reslizumab 3.0 mg/kg q4w (n=232)

Figure 4. Effect of reslizumab on (A) rate of asthma exacerbations and (B) lung function: the BREATHE trials (48). (A) In two separate trials, reslizumab
reduced the rate of asthma exacerbations with a pooled relative reduction in the asthma exacerbation rate of 54% (95% confidence interval, 42–63%) over
52 weeks. (B) Additionally, reslizumab improved lung function as measured by FEV1 by 110 ml (95% confidence interval, 67–150 ml) more than placebo.
**P , 0.01; ***P , 0.001. LS = least squares; q4w = every 4 weeks.

438 American Journal of Respiratory and Critical Care Medicine Volume 199 Number 4 | February 15 2019
CONCISE CLINICAL REVIEW

A Change from Baseline in Oral Glucocorticoid Dose B Time to First Asthma Exacerbation

Patients with an Exacerbation (%)

50 Placebo 100 Placebo
Benralizumab 30 mg, every 4 wk 90 Benralizumab 30 mg, every 4 wk
25
Median Change (%)

Benralizumab 30 mg, every 8 wk 80 Benralizumab 30 mg, every 8 wk

0 70
60
–25 50
40
–50
30
–75 20
10
–100 0
02 4 8 12 16 20 24 28 0 4 8 12 16 20 24 28
Week Week
Figure 5. Effect of benralizumab on (A) time to first asthma exacerbation and (B) oral corticosteroid reduction: the ZONDA trial (55). (A) In the ZONDA trial,
benralizumab dosed every 4 weeks or every 8 weeks led to a median percentage reduction from baseline in steroid requirement of 75% compared with a
25% reduction with placebo (P , 0.001). (B) As shown using a Kaplan-Meier cumulative incidence curve, benralizumab was associated with a longer time
to first asthma exacerbation when administered every 4 weeks (hazard ratio [HR], 0.39; 95% confidence interval [CI], 0.22–0.66) or every 8 weeks (HR,
0.32; CI, 0.17–0.57). Error bars show 95% confidence intervals around the least squares mean.

100 mg subcutaneous dosing was modest Anti–IL-4/IL-13 through STAT-6 (signal transducer and
in the SIRIUS study (43). A small study activator of transcription 6) phosphorylation,
of 10 patients with severe uncontrolled Dupilumab. Targeting IL-4 (65) or IL-13 regulate both iNOS (inducible nitric oxide
asthma on 100 mg subcutaneous alone (66) has been disappointing, probably synthase) and the mucin 5AC gene and
mepolizumab showed significant decline because targeting only one of these mucus production, it is not surprising that
in AEC; however, an increased sputum cytokines does not abrogate airway FENO was a predictor of clinical response
inflammation (66–68). Dupilumab is a to dupilumab. Dupilumab has a favorable
eosinophil count correlated with asthma
mAb that targets the IL-4a receptor and safety profile, with common side effects
exacerbations (60). This lower dose of
blocks signaling of both IL-4 and IL-13, key including injection site reaction and
mepolizumab does not appear to suppress cytokines that promote production of IgE transient blood eosinophilia. Dupilumab
the local eosinophilopoietic activity, as and recruitment of inflammatory cells has been approved by the FDA for the
evidenced by persistent airway eosinophil in addition to stimulating goblet cell treatment of atopic dermatitis and was
progenitor cells and ILC-2 cells that are a hyperplasia and modulating airway recently approved for asthma.
source of IL-5 (60, 61). Higher doses of hyperresponsiveness and airway
anti–IL-5 mAbs, administered to these remodeling (69). Dupilumab has been
shown to reduce asthma exacerbations, Selection of Biologic for Severe
patients in the form of intravenous weight-
rapidly improve lung function, and Uncontrolled Asthma
adjusted reslizumab (62), attenuated both
decrease OCS use while decreasing levels The majority of the aforementioned RCTs
sputum eosinophils and eosinophil on biologics in patients with uncontrolled
peroxidase and were associated with of T2 inflammation (FENO, thymus and
activation-regulated chemokine, eotaxin-3, severe asthma have demonstrated a
improvement in asthma control. However, significant response to placebo with
these studies are limited by the lack of and IgE) in moderate to severe asthma
reductions in exacerbations, improvement
head-to-head comparisons of the three (70, 71). The benefits of dupilumab were
in lung function, and improvement in
greater in subjects with higher baseline
anti–IL-5 mAbs in patients with similar patient-reported outcomes. These findings
AEC and FENO levels (71). In patients suggest that “severe asthma” is not
entry criteria, which are sorely needed.
The presence of Ig-bound IL-5 in the previously dependent on OCS, dupilumab intrinsically severe but often poorly
sputum of patients receiving low-dose was found to significantly reduce OCS use controlled (74, 75). Therefore, these
mepolizumab, with simultaneous increases by 70%, and nearly half of patients were studies suggest that although targeting
in free IL-5 and IgG autoantibodies (63), able to discontinue OCS. These OCS the T2 cytokines with biologics may
suggests the possibility of immune complex reductions occurred while reducing improve asthma control, many
aggregation and subsequent inflammation. exacerbation rates by 60% and improving patients may not actually need them.
These immune complexes formed between lung function (72) (Figure 7). Dupilumab Improving affordability, availability, and
cytokines and mAbs when inadequate levels has improved outcomes in patients with accessibility to ICS and long-acting
of drug reach the target tissues can increase symptomatic chronic rhinosinusitis and bronchodilators, as well as emphasizing
the in vivo potency of the bound cytokine nasal polyposis and should be considered the principles of asthma management,
(64). Interestingly, there was simultaneous in patients with asthma with this such as shared decision making,
increase in IL-51 ILC-2s, sputum IL-5, and comorbidity (73). encouraging adherence, good inhaler
Ig-bound IL-5 in those who experienced Unlike the anti–IL-5 RCTs, baseline technique, and allergen avoidance, are
worsening with low-dose anti–IL-5 therapy FENO was a predictor of clinical response sufficient to control symptoms and
(63). to dupilumab. Because IL-4 and IL-13, prevent asthma exacerbations in the vast

Concise Clinical Review 439

 CONCISE CLINICAL REVIEW

Because no head-to-head comparisons

have been made between these biologics,
claims of superiority of one biologic over
the other as made by indirect treatment
comparisons using metaregression and
matching-adjusted strategies (76–78)
may be invalid and misleading. Overall,
Block mature eos and all five of the currently approved biologics
eos progenitor and for severe asthma seem to reduce
ILC2 cells (benralizumab) exacerbation rates by approximately 50%,
with greater effects with higher baseline
AEC. Because the predominant biological
role of IL-5 is limited to eosinophil
maturation, survival, and recruitment into
the airway, it is logical to expect
that the effects of anti–IL-5 would be
Allergens predominantly seen in those patients whose
airflow obstruction, symptoms, and severity
ILC2 are driven by luminal eosinophils.
However, the roles of IL-4 and IL-13
Homing
(acting through the common IL-4R)
IL-5 IL-13
are more pleiotropic, with effects on
Infection eosinophil recruitment, goblet cell
Block eos progenitor cell
migration primed by IL-13 hyperplasia and mucus secretion, smooth
Block local and (dupilumab?) or by muscle contraction, and hyperresponsiveness.
systemic IL-5 Hemopoietic TSLP (tezepelumab?)
High dose anti-IL-5 progenitor Therefore, the beneficial effects of anti–IL-
(e.g., i.v. mepolizumab IL-13+SDF-1 4/13 treatment would be expected in a
or i.v. reslizumab) broader population of patients and not
IL-3 necessarily only in those with significant
IL-5 airway eosinophilia (79).
IL-9 A more precise understanding
GM-CSF of patient characteristics that would
Eotaxin elucidate the greatest benefit from a
SDF-1 specific biologic would be helpful. Use of
predictive biomarkers could also help
Bone marrow clinicians decide which biologic would
lead to the most beneficial response. In
Figure 6. Schematic of airway (luminal) eosinophils and eosinophilopoeitic factors with anti–IL-5
addition, use of biomarkers and clinical
therapy in severe eosinophilic asthma. In response to a variety of airway stimuli (such as allergens, indicators of response to biologic therapy
microbes, pollutants, etc.), CD4 (classic T-helper cell type 2 [Th2] response) or non-CD4 cells (such as earlier in the treatment course would
type 2 innate lymphoid cells [ILC2] in the airways, nonclassic T2 response), secrete eosinophilopoeitic allow for earlier adjustment to treatment
cytokines such as IL-5 and IL-13. In patients with severe asthma who are on high doses of systemic regimens.
corticosteroids, airway ILC2 cells may dominate over CD4 cells as the predominant source of IL-5 and Unfortunately, omalizumab has
IL-13. Although IL-13 can prime the migrational response of eosinophil progenitor cells from the bone no biomarker that has been useful for
marrow into the lung in response to SDF-1 (stromal-derived factor-1), locally derived IL-5 can promote predicting or monitoring response. For all
their “in situ differentiation” into mature eosinophils. Pharmacokinetic data of airway levels of biologics three anti–IL-5 mAbs, higher baseline AEC
have never been evaluated. Clinically relevant doses have been selected based on mathematical
and a history of exacerbations predict
modeling of airway levels of drugs from studies in normal volunteers or subjects with mild asthma and
from pharmacodynamics studies guided by absolute blood eosinophil levels. In order to suppress airway
enhanced response to the biologic. The
eosinophils, treatment options may include higher levels of anti–IL-5 neutralizing monoclonal antibodies presence of neutralizing antidrug antibodies
such as reslizumab or mepolizumab, or inhibition of the migration of progenitor cells into the airways has been low and not associated with loss of
(e.g., anti–IL-4R or antialarmins such as anti-TSLP [thymic stromal lymphopoietin] or anti–IL-33), or efficacy or predictive of side effects. In
depletion of both mature and immature eosinophils and possibly the ILC2 cells (those that express addition, baseline OCS use, history of
IL-5R) by the antibody-dependent cell–mediated cytotoxicity action of benralizumab. eos = eosinophils; nasal polyps, and prebronchodilator FVC
GM-CSF = granulocyte–macrophage colony–stimulating factor. Illustration by Patricia Ferrer Beals. less than 65% predicted were associated
with enhanced response to benralizumab
majority of patients. In the patients with medications) or those who require chronic in reducing exacerbations, regardless
more severe disease who require three OCS to maintain asthma control, biologics of baseline AEC (80). These findings
or more courses of OCS a year have a more important role in disease suggest that patients with these phenotypes
(despite adhering to their controller management. (OCS dependent, nasal polyposis, reduced

440 American Journal of Respiratory and Critical Care Medicine Volume 199 Number 4 | February 15 2019
CONCISE CLINICAL REVIEW

A Percentage Reduction in Oral Glucocorticoid Dose B Change from Baseline in FEV1 before Bronchodilator Use

Change from Baseline in FEV1 (liters)

0 0.30
Dupilumab
Percentage Reduction in Oral

0.25
Glucocorticoid Dose

–20 Primary
0.20
end point

0.15
–40
0.10
Placebo
0.05 Placebo
–60
Dupilumab P<0.001 0.00

–80 –0.05
0 4 8 12 16 20 24 0 2 4 6 8 12 16 20 24
Week Week
Figure 7. Effect of dupilumab on (A) percentage reduction in oral corticosteroid dosing and (B) lung function: the VENTURE trial (72). (A) In the VENTURE
trial, the least squares mean percentage reduction in oral corticosteroid dosing in patients receiving dupilumab at 24 weeks was 270.1% (SE of 64.9%)
compared with 241.9% (SE of 64.5%) in the group treated with placebo (P , 0.001). (B) At 24 weeks, dupilumab treatment resulted in a 220-ml (95%
confidence interval, 90–340 ml) improvement in FEV1 compared with placebo. Error bars show the SE.

lung function, and exacerbators) are most AEC, and decreased markers of T2 this specific patient population. In those
likely to respond to anti–IL-5 therapy. inflammation, IgE and FENO (82). patients who truly have severe asthma
Response biomarkers measured Tezepelumab and other biologics that (and not one of the masqueraders) and
early in the course of therapy (e.g., drop target upstream T2 inflammation may whose luminal obstruction and asthma
in eosinophil count after anti–IL-5 provide additional options for patients severity are predominantly mediated by
administration) do not appear to predict with uncontrolled noneosinophilic asthma eosinophils, anti–IL-5 mAbs are the therapy
long-term response. Use of clinical in the future. Biologics and small- of choice. In patients whose luminal
indicators (improved FEV1 > 100 ml molecule antagonists targeting kinases obstruction and severity may be driven
or Asthma Control Questionnaire score > (e.g., Janus kinase pathways) that are by factors such as mucus production,
0.5) within the first 16 weeks of treatment downstream of these T2 cytokines are also eosinophils, and smooth muscle contraction
with reslizumab predicted long-term being developed (83). and remodeling, an anti–IL-4R mAb may be
response (81). These clinical indicators Alternative modes of delivery of the therapy of choice. Finally, patients with
are easily measured by asthma specialists biologic therapies besides subcutaneous or asthma that is clearly driven by a clinical
and can allow shared decision making intravenous are being evaluated. Plasma history of allergies (rather than just an
with the patient early in the course of concentrations of biologics after intravenous elevated IgE level) are candidates for
therapy to decide if the biologic should administration are considerably higher than anti-IgE therapy; however, anti–IL-5 mAbs
be continued or if a switch to alternate BAL concentrations (84). To increase drug may also be effective in some of these
treatment is indicated. concentration in the terminal bronchioles patients. If a patient’s asthma is severe
while decreasing systemic toxicity, researchers enough to require maintenance OCS, there
are studying nebulized biologic therapy. is insufficient evidence to recommend
Future Biologics A recent animal study evaluating the anti-IgE therapy, as allergies may not be
use of a nebulizer to deliver fragments driving the need for OCS. There is a need to
With improved understanding of the of anti–IL-13 mAbs to the terminal study and develop new biologics that will
immunopathogenesis of asthma, additional bronchioles demonstrated a reduction in improve outcomes in patients with
inflammatory pathways have been identified allergic airway response and was well noneosinophilic or T2-low disease. Novel
as therapeutic targets, and new biologic tolerated (85, 86). imaging strategies (87, 88) and
agents are being developed. Although the immunoendotyping to develop new
currently FDA-approved biologics all target biomarkers (89) may lead to precise
downstream pathways of T2 inflammation, Conclusions methods to identify the specific patients
researchers are studying various upstream for the appropriate therapies. Finally, the
targets of T2 inflammation, including IL-25, Most patients with asthma, fortunately, possibility of earlier initiation of biologics
IL-33, and TSLP (Figure 1 and Table 3). In do not need a biologic if they are adherent to alter disease progression is exciting and
a recent phase 2 RCT of patients with with their usual controller medications. needs to be explored. n
moderate asthma, tezepelumab, a mAb Recognition of eosinophilic airway
against an alarmin, TSLP, reduced inflammation as a treatable trait has allowed Author disclosures are available with the text
asthma exacerbations unrelated to baseline for the emergence of biologic therapy in of this article at www.atsjournals.org.

Concise Clinical Review 441

 Table 3. Other Biologics and Small Molecules under Development for Type 2 Inflammatory Diseases

442
Mode of Current
Agent Clinical Trial Number Mode of Action Administration Clinical Phase Investigated Patient Populations

Asapiprant (90) Prostaglandin D2 antagonist Oral Preclinical, 3 for Allergic asthma, allergic rhinitis
allergic
rhinitis

RPC4046 (91) NCT02098473 IL-13R antagonist/anti–IL-13 s.c./i.v. 2 for EoE, 1 in EoE, moderate to severe asthma
mAb asthma

ADC3680/ADC3608B NCT01730027 CRTh2 antagonist Oral 2 Inadequately controlled asthma

(92)

AMG-282/RG6149 NCT01928368, NCT02170337 IL-33 antagonist/anti–IL-33 s.c./i.v. 2 for asthma, 1 Mild atopic asthma, CRSwNP
mAb for CRSwNP

ANB020 (93) NCT03469934, NCT02920021 IL-33 antagonist/anti–IL-33 s.c./i.v. 2 Severe asthma (eosinophilic
mAb phenotype), peanut allergy, AD

SB010 (94) NCT01743768 Anti-GATA3 DNAzyme Oral 2 Mild asthma

GSK3772847 NCT03207243 IL-33 antagonist/anti–IL-33 i.v. 2 Moderate to severe asthma

mAb

MK-1029 (95) NCT02720081 CRTh2 antagonist Oral 2 Persistent asthma uncontrolled by

montelukast

SAR440340/REGN3500 NCT03387852 IL-33 antagonist/anti–IL-33 s.c. 2 Moderate to severe asthma

mAb

Timapiprant NCT02002208 CRTh2 antagonist Oral 2 Severe asthma of eosinophilic

phenotype, moderate to severe AD

Fevipiprant NCT03215758, NCT01785602 CRTh2 antagonist Oral 3 for asthma, 2 Uncontrolled asthma, moderate to
in AD severe AD

Tezepelumab NCT03347279 TSLP antagonist s.c. 3 Inadequately controlled severe

asthma

Lebrikizumab (96) NCT02340234 IL-13R antagonist/anti–IL-13 s.c. Discontinued in Uncontrolled asthma with ICS,
mAb asthma, 2 in moderate to severe AD
AD

Tralokinumab (97) NCT03131648 IL-13R antagonist/anti–IL-13 s.c. Discontinued in Uncontrolled asthma, AD

mAb asthma, 3 in
AD

Definition of abbreviations: AD = atopic dermatitis; CRSwNP = chronic rhinosinusitis without nasal polyps; CRTh2 = chemoattractant receptor–homologous molecule expressed on T-helper
type 2 cells; EoE = eosinophilic esophagitis; ICS = inhaled corticosteroid; mAb = monoclonal antibody; TSLP = thymic stromal lymphopoietin.
CONCISE CLINICAL REVIEW

American Journal of Respiratory and Critical Care Medicine Volume 199 Number 4 | February 15 2019
CONCISE CLINICAL REVIEW

References 23. Holgate ST, Chuchalin AG, Hébert J, Lötvall J, Persson GB, Chung KF,
et al.; Omalizumab 011 International Study Group. Efficacy and safety
1. To T, Stanojevic S, Moores G, Gershon AS, Bateman ED, Cruz AA, et al. of a recombinant anti-immunoglobulin E antibody (omalizumab) in
Global asthma prevalence in adults: findings from the cross-sectional severe allergic asthma. Clin Exp Allergy 2004;34:632–638.
world health survey. BMC Public Health 2012;12:204. 24. Solèr M, Matz J, Townley R, Buhl R, O’Brien J, Fox H, et al. The anti-IgE
2. Moore WC, Bleecker ER, Curran-Everett D, Erzurum SC, Ameredes BT, antibody omalizumab reduces exacerbations and steroid requirement
Bacharier L, et al.; National Heart, Lung, Blood Institute’s Severe in allergic asthmatics. Eur Respir J 2001;18:254–261.
Asthma Research Program. Characterization of the severe asthma 25. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa
phenotype by the National Heart, Lung, and Blood Institute’s Severe GD, et al. Omalizumab, anti-IgE recombinant humanized monoclonal
Asthma Research Program. J Allergy Clin Immunol 2007;119:405–413. antibody, for the treatment of severe allergic asthma. J Allergy Clin
3. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. Immunol 2001;108:184–190.
International ERS/ATS guidelines on definition, evaluation and 26. Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, Liu AH, et al.
treatment of severe asthma. Eur Respir J 2014;43:343–373. [Published Randomized trial of omalizumab (anti-IgE) for asthma in inner-city
erratum appears in Eur Respir J 52:1352020.] children. N Engl J Med 2011;364:1005–1015.
4. Antonicelli L, Bucca C, Neri M, De Benedetto F, Sabbatani P, Bonifazi F, 27. Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, et al.
et al. Asthma severity and medical resource utilisation. Eur Respir J Benefits of omalizumab as add-on therapy in patients with severe
2004;23:723–729. persistent asthma who are inadequately controlled despite best
5. Hyland ME, Whalley B, Jones RC, Masoli M. A qualitative study of the available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy
impact of severe asthma and its treatment showing that treatment 2005;60:309–316.
burden is neglected in existing asthma assessment scales. Qual Life 28. Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J,
Res 2015;24:631–639. et al. Omalizumab in severe allergic asthma inadequately controlled
6. Carr TF, Kraft M. Management of severe asthma before referral to with standard therapy: a randomized trial. Ann Intern Med 2011;154:
the severe asthma specialist. J Allergy Clin Immunol Pract 2017;5: 573–582.
877–886. 29. Niven RM, Saralaya D, Chaudhuri R, Masoli M, Clifton I, Mansur AH,
7. Wenzel SE, Schwartz LB, Langmack EL, Halliday JL, Trudeau JB, Gibbs et al. Impact of omalizumab on treatment of severe allergic asthma in
RL, et al. Evidence that severe asthma can be divided pathologically UK clinical practice: a UK multicentre observational study (the APEX
into two inflammatory subtypes with distinct physiologic and clinical II study). BMJ Open 2016;6:e011857.
characteristics. Am J Respir Crit Care Med 1999;160:1001–1008. 30. Casale TB, Luskin AT, Busse W, Zeiger RS, Trzaskoma B, Yang M,
8. Anderson GP. Endotyping asthma: new insights into key pathogenic et al. Omalizumab effectiveness by biomarker status in patients with
mechanisms in a complex, heterogeneous disease. Lancet 2008;372: asthma: evidence from PROSPERO, a prospective real-world study. J
1107–1119. Allergy Clin Immunol Pract [online ahead of print] 22 May 2018; DOI:
9. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular 10.1016/j.jaip.2018.04.043.
approaches. Nat Med 2012;18:716–725. 31. Hanania NA, Wenzel S, Rosén K, Hsieh HJ, Mosesova S, Choy DF,
10. Pavord ID, Brightling CE, Woltmann G, Wardlaw AJ. Non-eosinophilic et al. Exploring the effects of omalizumab in allergic asthma: an
corticosteroid unresponsive asthma. Lancet 1999;353:2213–2214. analysis of biomarkers in the EXTRA study. Am J Respir Crit Care
Med 2013;187:804–811.
11. Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, et al.
T-helper type 2-driven inflammation defines major subphenotypes of 32. Garcia G, Magnan A, Chiron R, Contin-Bordes C, Berger P, Taillé C,
asthma. Am J Respir Crit Care Med 2009;180:388–395. et al. A proof-of-concept, randomized, controlled trial of omalizumab
in patients with severe, difficult-to-control, nonatopic asthma. Chest
12. Fahy JV. Type 2 inflammation in asthma–present in most, absent in
2013;144:411–419.
many. Nat Rev Immunol 2015;15:57–65.
33. Ledford D, Busse W, Trzaskoma B, Omachi TA, Rosén K, Chipps BE,
13. Israel E, Reddel HK. Severe and difficult-to-treat asthma in adults.
et al.. A randomized multicenter study evaluating Xolair persistence
N Engl J Med 2017;377:965–976.
of response after long-term therapy. J Allergy Clin Immunol 2017;
14. Godar M, Blanchetot C, de Haard H, Lambrecht BN, Brusselle G.
140:162–169, e2.
Personalized medicine with biologics for severe type 2 asthma:
34. Corren J, Casale TB, Lanier B, Buhl R, Holgate S, Jimenez P.
current status and future prospects. MAbs 2018;10:34–45.
Safety and tolerability of omalizumab. Clin Exp Allergy 2009;39:
15. Bullens DM, Truyen E, Coteur L, Dilissen E, Hellings PW, Dupont LJ,
788–797.
et al. IL-17 mRNA in sputum of asthmatic patients: linking T cell
35. Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A,
driven inflammation and granulocytic influx? Respir Res 2006;7:135.
et al.; MENSA Investigators. Mepolizumab treatment in patients with
16. Gibson PG, Yang IA, Upham JW, Reynolds PN, Hodge S, James AL, severe eosinophilic asthma. N Engl J Med 2014;371:1198–1207.
et al. Effect of azithromycin on asthma exacerbations and quality 36. Wenzel SE. Asthma: defining of the persistent adult phenotypes.
of life in adults with persistent uncontrolled asthma (AMAZES): a Lancet 2006;368:804–813.
randomised, double-blind, placebo-controlled trial. Lancet 2017;390: 37. Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding
659–668. P, et al. Asthma exacerbations and sputum eosinophil counts: a
17. Humbert M, Busse W, Hanania NA, Lowe PJ, Canvin J, Erpenbeck VJ, randomised controlled trial. Lancet 2002;360:1715–1721.
et al. Omalizumab in asthma: an update on recent developments. 38. Walsh GM. An update on biologic-based therapy in asthma. Immunotherapy
J Allergy Clin Immunol Pract 2014;2:525–536, e1. 2013;5:1255–1264.
18. Novak N, Bieber T. Allergic and nonallergic forms of atopic diseases. 39. Pelaia C, Calabrese C, Vatrella A, Busceti MT, Garofalo E, Lombardo N,
J Allergy Clin Immunol 2003;112:252–262. et al. Benralizumab: from the basic mechanism of action to the
19. Manka LA, Wechsler ME. Selecting the right biologic for your patients potential use in the biological therapy of severe eosinophilic asthma.
with severe asthma. Ann Allergy Asthma Immunol 2018;121:406–413. BioMed Res Int 2018;2018:4839230.
20. McCracken JL, Tripple JW, Calhoun WJ. Biologic therapy in the 40. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A,
management of asthma. Curr Opin Allergy Clin Immunol 2016;16: et al. Mepolizumab and exacerbations of refractory eosinophilic
375–382. asthma. N Engl J Med 2009;360:973–984.
21. Teach SJ, Gill MA, Togias A, Sorkness CA, Arbes SJ Jr, Calatroni A, 41. Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A,
et al. Preseasonal treatment with either omalizumab or an inhaled Pizzichini E, et al. Mepolizumab for prednisone-dependent asthma
corticosteroid boost to prevent fall asthma exacerbations. J Allergy with sputum eosinophilia. N Engl J Med 2009;360:985–993.
Clin Immunol 2015;136:1476–1485. 42. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON,
22. Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for et al. Mepolizumab for severe eosinophilic asthma (DREAM): a
asthma in adults and children. Cochrane Database Syst Rev 2014;(1): multicentre, double-blind, placebo-controlled trial. Lancet 2012;380:
CD003559. 651–659.

Concise Clinical Review 443

 CONCISE CLINICAL REVIEW

43. Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey 61. Menzies-Gow A, Flood-Page P, Sehmi R, Burman J, Hamid Q,
SW, et al.; SIRIUS Investigators. Oral glucocorticoid-sparing effect Robinson DS, et al. Anti-IL-5 (mepolizumab) therapy induces bone
of mepolizumab in eosinophilic asthma. N Engl J Med 2014;371: marrow eosinophil maturational arrest and decreases eosinophil
1189–1197. progenitors in the bronchial mucosa of atopic asthmatics. J Allergy
44. Magnan A, Bourdin A, Prazma CM, Albers FC, Price RG, Yancey SW, Clin Immunol 2003;111:714–719.
et al. Treatment response with mepolizumab in severe eosinophilic 62. Mukherjee M, Aleman Paramo F, Kjarsgaard M, Salter B, Nair G,
asthma patients with previous omalizumab treatment. Allergy 2016; LaVigne N, et al. Weight-adjusted intravenous reslizumab in severe
71:1335–1344. asthma with inadequate response to fixed-dose subcutaneous
45. Ortega HG, Yancey SW, Mayer B, Gunsoy NB, Keene ON, Bleecker mepolizumab. Am J Respir Crit Care Med 2018;197:38–46.
ER, et al. Severe eosinophilic asthma treated with mepolizumab 63. Mukherjee M, Lim HF, Thomas S, Miller D, Kjarsgaard M, Tan B,
stratified by baseline eosinophil thresholds: a secondary analysis et al. Airway autoimmune responses in severe eosinophilic asthma
of the DREAM and MENSA studies. Lancet Respir Med 2016;4: following low-dose mepolizumab therapy. Allergy Asthma Clin
549–556. Immunol 2017;13:2.
46. Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen 64. Mukherjee M, Nair P. Autoimmune responses in severe asthma. Allergy
LM, et al. Efficacy of mepolizumab add-on therapy on health-related Asthma Immunol Res 2018;10:428–447.
quality of life and markers of asthma control in severe eosinophilic 65. Corren J, Busse W, Meltzer EO, Mansfield L, Bensch G, Fahrenholz J,
asthma (MUSCA): a randomised, double-blind, placebo-controlled, et al. A randomized, controlled, phase 2 study of AMG 317, an
parallel-group, multicentre, phase 3b trial. Lancet Respir Med 2017; IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit
5:390–400. Care Med 2010;181:788–796.
47. Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, et al.; Res- 66. Hanania NA, Korenblat P, Chapman KR, Bateman ED, Kopecky P,
5-0010 Study Group. Reslizumab for poorly controlled, eosinophilic Paggiaro P, et al. Efficacy and safety of lebrikizumab in patients with
asthma: a randomized, placebo-controlled study. Am J Respir Crit uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase
Care Med 2011;184:1125–1132. 3, randomised, double-blind, placebo-controlled trials. Lancet Respir
48. Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Med 2016;4:781–796.
Bardin P, et al. Reslizumab for inadequately controlled asthma with 67. Panettieri RA Jr, Sjöbring U, Péterffy A, Wessman P, Bowen K, Piper E,
elevated blood eosinophil counts: results from two multicentre, et al. Tralokinumab for severe, uncontrolled asthma (STRATOS 1
parallel, double-blind, randomised, placebo-controlled, phase 3 and STRATOS 2): two randomised, double-blind, placebo-controlled,
trials. Lancet Respir Med 2015;3:355–366. phase 3 clinical trials. Lancet Respir Med 2018;6:511–525.
49. Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. 68. Russell RJ, Chachi L, FitzGerald JM, Backer V, Olivenstein R, Titlestad
Reslizumab for inadequately controlled asthma with elevated blood IL, et al.; MESOS Study Investigators. Effect of tralokinumab, an
eosinophil levels: a randomized phase 3 study. Chest 2016;150:789–798. interleukin-13 neutralising monoclonal antibody, on eosinophilic
50. Corren J, Weinstein S, Janka L, Zangrilli J, Garin M. Phase 3 study of airway inflammation in uncontrolled moderate-to-severe asthma
reslizumab in patients with poorly controlled asthma: effects across (MESOS): a multicentre, double-blind, randomised, placebo-
a broad range of eosinophil counts. Chest 2016;150:799–810. controlled phase 2 trial. Lancet Respir Med 2018;6:499–510.
51. Farne HA, Wilson A, Powell C, Bax L, Milan SJ. Anti-IL5 therapies for 69. Pepper AN, Renz H, Casale TB, Garn H. Biologic therapy and novel
asthma. Cochrane Database Syst Rev 2017;9:CD010834. molecular targets of severe asthma. J Allergy Clin Immunol Pract
52. Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW, 2017;5:909–916.
et al. Benralizumab, an anti-interleukin 5 receptor a monoclonal 70. Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, et al.
antibody, versus placebo for uncontrolled eosinophilic asthma: a Dupilumab efficacy and safety in adults with uncontrolled persistent
phase 2b randomised dose-ranging study. Lancet Respir Med 2014; asthma despite use of medium-to-high-dose inhaled corticosteroids
2:879–890. plus a long-acting b2 agonist: a randomised double-blind placebo-
53. Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, controlled pivotal phase 2b dose-ranging trial. Lancet 2016;388:31–44.
et al.; SIROCCO Study Investigators. Efficacy and safety of 71. Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al.
benralizumab for patients with severe asthma uncontrolled with Dupilumab efficacy and safety in moderate-to-severe uncontrolled
high-dosage inhaled corticosteroids and long-acting b2-agonists asthma. N Engl J Med 2018;378:2486–2496.
(SIROCCO): a randomised, multicentre, placebo-controlled phase 3 72. Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, et al.
trial. Lancet 2016;388:2115–2127. Efficacy and safety of dupilumab in glucocorticoid-dependent severe
54. FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, asthma. N Engl J Med 2018;378:2475–2485.
et al.; CALIMA Study Investigators. Benralizumab, an anti- 73. Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson BJ, Gevaert P,
interleukin-5 receptor a monoclonal antibody, as add-on treatment et al. Effect of subcutaneous dupilumab on nasal polyp burden in
for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): patients with chronic sinusitis and nasal polyposis: a randomized
a randomised, double-blind, placebo-controlled phase 3 trial. Lancet clinical trial. JAMA 2016;315:469–479.
2016;388:2128–2141. 74. Nair P. Anti-interleukin-5 monoclonal antibody to treat severe eosinophilic
55. Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, et al.; asthma. N Engl J Med 2014;371:1249–1251.
ZONDA Trial Investigators. Oral glucocorticoid-sparing effect of 75. Lacy P, Nair P. The human eosinophil. In: Greer J, Arber D, Glader B,
benralizumab in severe asthma. N Engl J Med 2017;376:2448–2458. Lost A, Means R, Paraskevas F, et al., editors. Wintrobe’s clinical
56. Chipps BE, Newbold P, Hirsch I, Trudo F, Goldman M. Benralizumab hematology, 14th ed. Philadelphia, PA: Lippincott Williams & Wilkins;
efficacy by atopy status and serum immunoglobulin E for patients 2018.
with severe, uncontrolled asthma. Ann Allergy Asthma Immunol 76. Busse W, Chupp G, Nagase H, Albers FC, Doyle S, Shen Q, et al.
2018;120:504–511, e4. Anti-IL-5 treatments in patients with severe asthma by blood
57. Fowler SJ, Tavernier G, Niven R. High blood eosinophil counts predict eosinophil thresholds: indirect treatment comparison. J Allergy Clin
sputum eosinophilia in patients with severe asthma. J Allergy Clin Immunol [online ahead of print] 8 Sept 2018; DOI: 10.1016/j.jaci.
Immunol 2015;135:822–824, e2. 2018.08.031.
58. Mukherjee M, Nair P. Blood or sputum eosinophils to guide asthma 77. Casale TB, Pacou M, Mesana L, Farge G, Sun SX, Castro M. Reslizumab
therapy? Lancet Respir Med 2015;3:824–825. compared with benralizumab in patients with eosinophilic asthma: a
59. Bhalla A, Mukherjee M, Nair P. Airway eosinophilopoietic and autoimmune systematic literature review and network meta-analysis. J Allergy Clin
mechanisms of eosinophilia in severe asthma. Immunol Allergy Clin Immunol Pract [online ahead of print] 11 Sept 2018; DOI: 10.1016/j.jaip.
North Am 2018;38:639–654. 2018.08.036.
60. Sehmi R, Smith SG, Kjarsgaard M, Radford K, Boulet LP, Lemiere C, 78. Bourdin A, Husereau D, Molinari N, Golam S, Siddiqui MK, Lindner L,
et al. Role of local eosinophilopoietic processes in the development et al. Matching-adjusted indirect comparison of benralizumab versus
of airway eosinophilia in prednisone-dependent severe asthma. Clin interleukin-5 inhibitors: systematic review. Eur Respir J 2018;52:
Exp Allergy 2016;46:793–802. 1801393.

444 American Journal of Respiratory and Critical Care Medicine Volume 199 Number 4 | February 15 2019
CONCISE CLINICAL REVIEW

79. Robinson D, Humbert M, Buhl R, Cruz AA, Inoue H, Korom S, et al. 89. Kuo CS, Pavlidis S, Loza M, Baribaud F, Rowe A, Pandis I, et al.;
Revisiting Type 2-high and Type 2-low airway inflammation in U-BIOPRED Study Group. T-helper cell type 2 (Th2) and non-Th2
asthma: current knowledge and therapeutic implications. Clin Exp molecular phenotypes of asthma using sputum transcriptomics in
Allergy 2017;47:161–175. U-BIOPRED. Eur Respir J 2017;49:1602135.
80. Bleecker ER, Wechsler ME, FitzGerald JM, Menzies-Gow A, Wu Y, Hirsch 90. Takahashi G, Asanuma F, Suzuki N, Hattori M, Sakamoto S, Kugimiya
I, et al. Baseline patient factors impact on the clinical efficacy of A, et al. Effect of the potent and selective DP1 receptor antagonist,
benralizumab for severe asthma. Eur Respir J 2018;52:1800936. asapiprant (S-555739), in animal models of allergic rhinitis and
81. Bateman ED, Zangrilli J, Germinaro M, Weiss S, Castro M. Association allergic asthma. Eur J Pharmacol 2015;765:15–23.
between early improvements in lung function and asthma control with 91. Tripp CS, Cuff C, Campbell AL, Hendrickson BA, Voss J, Melim T, et al.
reslizumab and the annual rate of asthma exacerbations [abstract]. Am RPC4046, a novel anti-interleukin-13 antibody, blocks IL-13 binding
J Respir Crit Care Med 2016;193:A7782. to IL-13 a1 and a2 receptors: a randomized, double-blind, placebo-
82. Corren J, Parnes JR, Wang L, Mo M, Roseti SL, Griffiths JM, et al. controlled, dose-escalation first-in-human study. Adv Ther 2017;34:
Tezepelumab in adults with uncontrolled asthma. N Engl J Med 1364–1381.
2017;377:936–946. 92. Singh D, Ravi A, Southworth T. CRTH2 antagonists in asthma: current
83. Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O’Shea JJ. JAK perspectives. Clin Pharmacol 2017;9:165–173.
inhibition as a therapeutic strategy for immune and inflammatory 93. Johnston LK, Bryce PJ. Understanding interleukin 33 and its roles in
diseases. Nat Rev Drug Discov 2017;17:78. eosinophil development. Front Med (Lausanne) 2017;4:51.
84. Hart TK, Cook RM, Zia-Amirhosseini P, Minthorn E, Sellers TS, Maleeff 94. Krug N, Hohlfeld JM, Kirsten AM, Kornmann O, Beeh KM, Kappeler D,
BE, et al. Preclinical efficacy and safety of mepolizumab (SB-240563), et al. Allergen-induced asthmatic responses modified by a GATA3-
a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. specific DNAzyme. N Engl J Med 2015;372:1987–1995.
J Allergy Clin Immunol 2001;108:250–257. 95. Norman P. Update on the status of DP2 receptor antagonists; from
85. Lightwood D, Tservistas M, Zehentleitner M, Sarkar K, Turner A, proof of concept through clinical failures to promising new drugs.
Bracher M, et al. Efficacy of an inhaled IL-13 antibody fragment in Expert Opin Investig Drugs 2014;23:55–66.
a model of chronic asthma. Am J Respir Crit Care Med 2018;198: 96. Liu Y, Zhang S, Chen R, Wei J, Guan G, Zhou M, et al. Meta-analysis
610–619. of randomized controlled trials for the efficacy and safety of anti-
86. Holguin F. Biological treatments for eosinophilic asthma enter the interleukin-13 therapy with lebrikizumab in patients with uncontrolled
airways. Am J Respir Crit Care Med 2018;198:551–552. asthma. Allergy Asthma Proc 2018;39:332–337.
87. Svenningsen S, Eddy RL, Lim HF, Cox PG, Nair P, Parraga G. Sputum 97. Chung KF. Tralokinumab unsuccessful for management of severe,
eosinophilia and magnetic resonance imaging ventilation heterogeneity in uncontrolled asthma. Lancet Respir Med 2018;6:480–481.
severe asthma. Am J Respir Crit Care Med 2018;197:876–884. 98. Expert insight into emerging clinical data and implications for future
88. Dunican EM, Elicker BM, Gierada DS, Nagle SK, Schiebler ML, Newell clinical decision-making and clinical practice. Presented in the
JD, et al.; National Heart Lung and Blood Institute (NHLBI) Severe symposium “Raising the clinical bar beyond current biologics in
Asthma Research Program (SARP). Mucus plugs in patients with uncontrolled persistent asthma: translating emerging data into future
asthma linked to eosinophilia and airflow obstruction. J Clin Invest clinical decisions” at the European Academy of Allergy and Clinical
2018;128:997–1009. Immunology meeting. May 2018, Munich, Germany.

Concise Clinical Review 445